Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2005 3
2006 1
2011 1
2012 1
2013 1
2014 1
2015 21
2016 8
2017 9
2018 7
2019 4
2020 5
2021 8
2022 12
2023 13
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Biological insights in non-small cell lung cancer.
Rosell R, Jain A, Codony-Servat J, Jantus-Lewintre E, Morrison B, Ginesta JB, González-Cao M. Rosell R, et al. Among authors: gonzalez cao m. Cancer Biol Med. 2023 Jun 28;20(7):500-18. doi: 10.20892/j.issn.2095-3941.2023.0108. Cancer Biol Med. 2023. PMID: 37381723 Free PMC article. Review.
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. Borghaei H, et al. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. Ann Oncol. 2024. PMID: 37866811 Clinical Trial.
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC).
Rosell R, Codony-Servat J, González J, Santarpia M, Jain A, Shivamallu C, Wang Y, Giménez-Capitán A, Molina-Vila MA, Nilsson J, González-Cao M. Rosell R, et al. Among authors: gonzalez cao m. Crit Rev Oncol Hematol. 2024 Mar;195:104228. doi: 10.1016/j.critrevonc.2023.104228. Epub 2023 Dec 9. Crit Rev Oncol Hematol. 2024. PMID: 38072173 Free article. Review.
Sequence of therapies for advanced BRAFV600E/K melanoma.
Gonzalez-Cao M, Rosell R, Martin Algarra S, Puertolas T, Espinosa E. Gonzalez-Cao M, et al. Ann Transl Med. 2023 Mar 31;11(6):270. doi: 10.21037/atm-23-165. Epub 2023 Feb 14. Ann Transl Med. 2023. PMID: 37082692 Free PMC article. No abstract available.
The role of biomarkers in stage III non-small cell lung cancer.
Rosell R, González-Cao M, Ito M, Santarpia M, Aguilar A, Codony-Servat J. Rosell R, et al. Among authors: gonzalez cao m. Expert Rev Respir Med. 2023 Jan-Jun;17(6):469-480. doi: 10.1080/17476348.2023.2223985. Epub 2023 Jun 15. Expert Rev Respir Med. 2023. PMID: 37317885 Review.
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
Santarpia M, Ciappina G, Spagnolo CC, Squeri A, Passalacqua MI, Aguilar A, Gonzalez-Cao M, Giovannetti E, Silvestris N, Rosell R. Santarpia M, et al. Among authors: gonzalez cao m. Transl Lung Cancer Res. 2023 Feb 28;12(2):346-368. doi: 10.21037/tlcr-22-639. Epub 2023 Feb 20. Transl Lung Cancer Res. 2023. PMID: 36895930 Free PMC article. Review.
Other targeted drugs in melanoma.
González-Cao M, Rodón J, Karachaliou N, Sánchez J, Santarpia M, Viteri S, Pilotto S, Teixidó C, Riso A, Rosell R. González-Cao M, et al. Ann Transl Med. 2015 Oct;3(18):266. doi: 10.3978/j.issn.2305-5839.2015.08.12. Ann Transl Med. 2015. PMID: 26605312 Free PMC article. Review.
Liquid biopsy for lung cancer early detection.
Santarpia M, Liguori A, D'Aveni A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, Lazzari C, Altavilla G, Rosell R. Santarpia M, et al. Among authors: gonzalez cao m. J Thorac Dis. 2018 Apr;10(Suppl 7):S882-S897. doi: 10.21037/jtd.2018.03.81. J Thorac Dis. 2018. PMID: 29780635 Free PMC article. Review.
99 results